Related Experiment Video
Updated: May 21, 2026
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma
Xin Tian1, Motao Zhu, Yanhua Tian
1CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China.
Abstract:
In the past few years, cell-derived membrane vesicle-based tumor vaccines have been considered as valuable new tools for cancer immunotherapy. Despite promising results in cancer clinical trails, an improved method is urgently needed for high efficiency tumor vaccines for a broad spectrum of tumors. Here we developed a single membrane vesicle-based vaccine, which is active in repressing both melanoma (B16) and Lewis lung carcinoma (LLC) tumor growth. By using the intrinsic function of dendritic cells in the processing and presentation of antigens, we generated dendritic cell (DC)-derived membrane vesicles (DC-mv) bearing tumor antigens from both B16 and LLC cells. Vaccination with this DC-mv-based dual vaccine induced specific cytotoxic T lymphocytes (CTL)-dependent tumor rejection and suppressed the growth of both types of tumor xenografts in mice. In addition, induction of CTL by this vaccine resulted in cross-protection responses and consequently enabled significant enhanced anti-tumor effects, indicating the synergistic anti-tumor activity. Our study suggests that the DC-mv-based vaccine holds great potential as a highly effective, versatile, cell-free vaccine for inhibition of multiple types of tumor growth.
Insights
This study developed a novel dendritic cell-derived membrane vesicle vaccine. This innovative cancer immunotherapy effectively suppressed melanoma and lung carcinoma tumor growth in mice.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cell-derived membrane vesicles are promising cancer immunotherapy tools.
- Existing tumor vaccines require improvement for broad efficacy and efficiency.
Purpose of the Study:
- To develop a single, highly efficient, and versatile membrane vesicle-based tumor vaccine.
- To target multiple tumor types, including melanoma and Lewis lung carcinoma.
Main Methods:
- Generated dendritic cell (DC)-derived membrane vesicles (DC-mv) presenting antigens from both B16 melanoma and LLC tumor cells.
- Vaccinated mice with the dual-antigen DC-mv vaccine.
- Assessed tumor rejection, cytotoxic T lymphocyte (CTL) induction, and cross-protection responses.
Main Results:
- The DC-mv vaccine effectively repressed both melanoma (B16) and Lewis lung carcinoma (LLC) tumor growth in mice.
- Vaccination induced specific CTL-dependent anti-tumor immunity.
- Observed cross-protection responses and synergistic anti-tumor effects.
Conclusions:
- DC-mv-based dual vaccines are a potent cell-free strategy for cancer immunotherapy.
- This approach shows potential for inhibiting multiple tumor types with enhanced efficacy.
- The vaccine's versatility and effectiveness suggest broad applicability in cancer treatment.
